ArticleAlimentary pharmacology & therapeutics2015
Immunopathogenesis of olmesartan-associated enteropathy.
Article in Alimentary pharmacology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- An Indolent Enteropathy Accelerated by Combination Immune Checkpoint Inhibitor Therapy.ACG case reports journal · 2026Article
- Not Only Enteropathy: The Overlooked "Gastric Side" of Olmesartan.Clinical case reports · 2026Article
- Article
- Olmesartan-associated enteropathy presenting with metabolic acidosis and acute kidney injury requiring hemodialysis: a rechallenge-confirmed case.CEN case reports · 2026Article
- Olmesartan-related sprue-like enteropathy presenting as severe diarrhoea.BMJ case reports · 2026Article
- When Treatment Hinders Healing-Angiotensin Receptor Blockers and Malabsorptive Risk in Patients with Celiac Disease.Digestive diseases and sciences · 2026Article
- Diagnostic clues in patients with clinical malabsorption and pathological small intestinal villous atrophy: Immune-mediated type and beyond.World journal of gastroenterology · 2026Review
- Use of Angiotensin Receptor Blockers in Celiac Disease Associated with Worse Outcomes.Digestive diseases and sciences · 2025Article
- Olmesartan-associated gastroduodenitis that was detected on endoscopic follow-up.Clinical journal of gastroenterology · 2025Article
- Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study.ESMO gastrointestinal oncology · 2024Article
- A Rare Case of Olmesartan-Associated Enteropathy Successfully Managed With Steroid Taper.Cureus · 2023Article
- Coeliac disease enteropathy and symptoms may be aggravated by angiotensin receptor blockers in patients on a gluten-free diet.United European gastroenterology journal · 2021Article
- Cutaneous ulcers in association with sprue-like enteropathy secondary to Losartan.Clinical case reports · 2021Article
- Olmesartan-Induced Enteropathy: A Case of Recurrent Diarrhoea.European journal of case reports in internal medicine · 2020Article
- Association of sprue-like enteropathy and angiotensin receptor-1 antagonists.Wiener klinische Wochenschrift · 2019Review
- A simple treatment for a potentially life-threatening cause of malabsorption.Internal and emergency medicine · 2019Article
- Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report.Current drug safety · 2019Article
- [Three cases of severe chronic diarrhea with a rare cause and a simple therapy].Der Internist · 2018Article
- Autoimmune enteropathies.Virchows Archiv : an international journal of pathology · 2018Review
- Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers.Intestinal research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundOlmesartan-associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue-like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil.
aimTo determine the mechanistic similarities of OAE with coeliac sprue.
methodsDuodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil). There were seven 'on/off' paired samples. Formalin-fixed biopsies were stained for CD8, CD4, FoxP3, IL-15R and psmad 2/3. Caco2 cells (human colonic epithelial line) were treated with olmesartan medoxomil and stained for IL-15, IL-15R and ZO-1.
resultsIn the 'on olmesartan medoxomil' duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil. IL15R expression is also increased with olmesartan medoxomil use. Evaluation of the effect of olmesartan medoxomil upon Caco-2 cells demonstrated that IL15 expression is increased in response to olmesartan medoxomil treatment. Further, ZO-1, a tight junction protein, is disrupted in olmesartan medoxomil-treated Caco-2 cells.
conclusionsOlmesartan-associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.